Literature DB >> 2055737

The use of iohexol in patients with previous reactions to ionic contrast material. A multicenter clinical trial.

R L Siegle1, R A Halvorsen, J Dillon, M L Gavant, E Halpern.   

Abstract

Patients who have had prior reactions to iodinated contrast material have increased risk for repeat reactions. Nonionic contrast agents have been reported to reduce the risk of contrast reactions. A multicenter study was undertaken to determine the repeat reaction rate using iohexol. Two hundred ninety-one repeat reactors were included in the study, of whom one-third received premedication. Sixteen patients (5.5%) experienced repeat reactions; none was severe, and only one was more serious than the prior reaction. This is in contrast to the reported 16% to 44% repeated reaction rate for ionic agents. We conclude that iohexol is effective in reducing the occurrence of repeat reactions from the level observed with ionic agents without premedication. Iohexol appears to be as effective as ionic agents plus premedication in this high-risk group of patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2055737     DOI: 10.1097/00004424-199105000-00004

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  4 in total

Review 1.  Reactions to radiocontrast material. Anaphylactoid events in radiology.

Authors:  P L Lieberman; R L Seigle
Journal:  Clin Rev Allergy Immunol       Date:  1999       Impact factor: 8.667

Review 2.  Adverse reactions to intravenous iodinated contrast media: a primer for radiologists.

Authors:  Saravanan Namasivayam; Mannudeep K Kalra; William E Torres; William C Small
Journal:  Emerg Radiol       Date:  2006-05-11

Review 3.  Contrast media toxicity in children.

Authors:  Robert C Brasch
Journal:  Pediatr Radiol       Date:  2008-05

Review 4.  Adverse effects of contrast media: incidence, prevention and management.

Authors:  H S Thomsen; W H Bush
Journal:  Drug Saf       Date:  1998-10       Impact factor: 5.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.